Please login to the form below

Not currently logged in
Email:
Password:

Gilead sues Teva over patent for HIV drug

Biopharmaceutical company Gilead Sciences has filed a lawsuit in the US against Teva for infringement of its patents for Truvada

Biopharmaceutical company Gilead Sciences has filed a lawsuit in the US against Teva for infringement of its patents for Truvada, an antiretroviral agent for the treatment of HIV-1 in adults.

Teva has submitted an Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration (FDA) requesting approval to manufacture and market a generic version of Truvada. Gilead has filed a lawsuit against the Israeli company as it claims it has two valid patents covering emtricitabine, a component of Truvada.

By filing a lawsuit, Gilead has temporarily put a stop to Teva's ANDA. The FDA is unable to approve the request for 30 months or until a court rules in favour of Teva.

Ten patents, all of which would need to be expired or invalidated before a generic version of the drug could be marketed, currently protect Truvada.

In November, PMLiVE reported that Cephalon and Eurand had filed a similar lawsuit against generic manufacturers Mylan and Barr relating to the muscle relaxant, Amrix.

As generic competition increases, we expect to see more manufacturers turning to the courts in a bid to defend their intellectual property.
 

15th December 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

Transforming healthcare through effective collaboration. Making work to feel proud of. www.dovetailstrategies.com...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics